Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation

被引:29
作者
Jang, Ji Eun [1 ]
Hyun, Shin Young [1 ]
Kim, Yun Deok [1 ]
Yoon, Sul Hee [1 ]
Hwang, Doh Yu [1 ]
Kim, Soo Jeong [1 ]
Kim, Yuri [1 ]
Kim, Jin Seok [1 ]
Cheong, June-Won [1 ]
Min, Yoo Hong [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Hematol, Seoul 120752, South Korea
关键词
CMV disease; allo-HSCT; Leukopenia; Prediction; BONE-MARROW-TRANSPLANTATION; REAL-TIME PCR; INFECTION; RECIPIENTS; REACTIVATION; THERAPY; RECONSTITUTION; SURVEILLANCE; GANCICLOVIR; PROPHYLAXIS;
D O I
10.1016/j.bbmt.2011.10.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytomegalovirus (CMV) disease is a major cause of infectious complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although patients undergoing allo-HSCT receive prophylactic and preemptive treatment for CMV, a subset of patients experience clinically significant CMV disease. This study investigated the risk factors for progression from CMV viremia to CMV disease during or after preemptive therapy in patients undergoing allo-HSCT. Between January 2006 and August 2010, 43 patients receiveel preemptive therapy for CMV viremia after allo-HSCT. These patients experienced 74 episodes of CMV viremia. Nine of the patients (21%) and 12 of the episodes (16%) progressed to CMV disease. Univariate analysis identified several risk factors for progression to CMV disease, including high initial viral load (P = .020), leukopenia (P = .012), and neutropenia (P = .033) at the time of detection of CMV viremia. On multivariate analysis, leukopenia remained an independent predictor (hazard ratio, 4.347; P = .045). The rate of failure to clear CMV viremia after I cycle of preemptive therapy was higher in the leukopenia group than in the non-leukopenia group (60.0% versus 16.9%; P = .002). This indicates that leukopenia initially documented with CMV viremia is related to lower viral response to preemptive therapy and is a notable risk factor for progression from CMV viremia to CMV disease. Biol Blood Marrow Transplant 18: 881-886 (2012) (C) 2012 American Society fir Blood and Marrow Transplantation
引用
收藏
页码:881 / 886
页数:6
相关论文
共 23 条
[1]   Relationship of Reconstituted Adaptive and Innate Cytomegalovirus (CMV)-Specific Immune Responses with CMV Viremia in Hematopoietic Stem Cell Transplant Recipients [J].
Barron, Michelle A. ;
Gao, Dexiang ;
Springer, Kathryn L. ;
Patterson, Julie A. ;
Brunvand, Mark W. ;
McSweeney, Peter A. ;
Zeng, Chang ;
Baron, Anna E. ;
Weinberg, Adriana .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (12) :1777-1783
[2]   QUANTITATIVE RELATIONSHIPS BETWEEN CIRCULATING LEUKOCYTES AND INFECTION IN PATIENTS WITH ACUTE LEUKEMIA [J].
BODEY, GP ;
BUCKLEY, M ;
SATHE, YS ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1966, 64 (02) :328-+
[3]   Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies [J].
Boeckh, M ;
Nichols, WG ;
Papanicolaou, G ;
Rubin, R ;
Wingard, JR ;
Zaia, Y .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (09) :543-558
[4]   How I treat cytomegalovirus in hematopoietic cell transplant recipients [J].
Boeckh, Michael ;
Ljungman, Per .
BLOOD, 2009, 113 (23) :5711-5719
[5]   The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients [J].
Buyck, H. C. ;
Prentice, H. G. F. ;
Griffiths, P. D. ;
Emery, V. C. .
BONE MARROW TRANSPLANTATION, 2010, 45 (07) :1212-1219
[6]   Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease [J].
Cantoni, Nathan ;
Hirsch, Hans H. ;
Khanna, Nina ;
Gerull, Sabine ;
Buser, Andreas ;
Bucher, Christoph ;
Halter, Joerg ;
Heim, Dominik ;
Tichelli, Andre ;
Gratwohl, Alois ;
Stern, Martin .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (09) :1309-1314
[7]   Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed [J].
Dodero, A ;
Carrabba, M ;
Milani, R ;
Rizzo, E ;
Raganato, A ;
Montefusco, V ;
Farina, L ;
Milanesi, M ;
Longoni, P ;
Carlo-Stella, C ;
Corradini, P .
EXPERIMENTAL HEMATOLOGY, 2005, 33 (08) :920-927
[8]   Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation [J].
Emery, VC ;
Sabin, CA ;
Cope, AV ;
Gor, D ;
Hassan-Walker, AF ;
Griffiths, PD .
LANCET, 2000, 355 (9220) :2032-2036
[9]  
ENRIGHT H, 1993, TRANSPLANTATION, V55, P1339
[10]   Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy [J].
George, B. ;
Pati, N. ;
Gilroy, N. ;
Ratnamohan, M. ;
Huang, G. ;
Kerridge, I. ;
Hertzberg, M. ;
Gottlieb, D. ;
Bradstock, K. .
TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (04) :322-329